Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jan;59(1):221-224.
doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

Matthew J Pianko  1 , Samuel A Funt  1 , David B Page  2 , Deepika Cattry  1 , Emma C Scott  3 , Stephen M Ansell  4 , Ivan M Borrello  5 , Martin Gutierrez  6 , Nikoletta Lendvai  1 , Hani Hassoun  1 , C Ola Landgren  1 , Alexander M Lesokhin  1
Affiliations
Clinical Trial

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

Matthew J Pianko et al. Leuk Lymphoma. 2018 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest:

A.M.L. reported research funding from BMS, Janssen, Genentech, and Serametrix, Consulting/Honoraria from Syndax, Aduro, Juno, Oncomed, BMS, Novartis, Janssen, and royalties from Serametrix. S.A.F. has stock ownership in Kite Pharma, D.B.P. reported research support from Medimmune, Merck, and IRX Therapeutics, and consultancy for Peregrine and Celgene. S.M.A. reported research funding from BMS, Merck, Seattle Genetics and Affimed. I.M.B. reported BMS research funding and consultancy. E.C.S. and M.G. reported BMS research funding. H.H. reported Takeda Consultancy and Research Funding; Celgene Research funding; Novartis Consultancy. M.J.P., D.C., N.L., and C.O.L. have no relevant disclosures.

Figures

Figure 1
Figure 1
(a) Involved serum paraprotein markers in 3 patients with relapsed myeloma receiving lenalidomide (without dexamethasone) after treatment with nivolumab. SFLC = serum free light chain (b) PD-1 receptor occupancy (RO) by nivolumab on CD3+ bone marrow mononuclear cells (BMMC) by mean fluorescence intensity (MFI) before nivolumab and at week 6 of therapy. Patients were treated every 21 days for the first two doses on study, and week 6 BMMC were collected prior to dose #3.
See this image and copyright information in PMC

References

    1. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552–9. Epub 2011/12/21. - PMC - PubMed
    1. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P Investigators E. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373:621–31. - PubMed
    1. Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med. 2015;7:280sr1. - PubMed
    1. Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Seminars in hematology. 2001;38:243–9. - PubMed
    1. Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood. 2015;126:2475–8. - PMC - PubMed

Substances

LinkOut - more resources